Avidita antifosfolipidových protilátek – naše současné znalosti

English version

Autoři: L. Fialová
Působiště autorů: Ústav lékařské biochemie a laboratorní diagnostiky, 1. lékařská fakulta, Univerzita Karlova v Praze a Všeobecná fakultní nemocnice v Praze
Vyšlo v časopise: Epidemiol. Mikrobiol. Imunol. 63, 2014, č. 3, s. 220-224
Kategorie: Souhrnná sdělení, původní práce, kazuistiky

Souhrn

Antifosfolipidové protilátky (APL), které představují sérový marker antifosfolipidového syndromu, zahrnují mimořádně heterogenní skupinu protilátek namířených proti různým fosfolipidům a proteinovým kofaktorům. Heterogenita APL se týká nejen specifity vazebných míst, ale také jejich avidity. Cílem studie bylo shrnout dosavadní znalosti o běžně užívaných postupech pro stanovení avidity se speciálním zaměřením na APL a zhodnocení jejího klinického významu. Často užívanou technikou pro stanovení avidity protilátek jsou ELISA metody v přítomnosti různých chaotropních látek. Nálezy klinických studií ukazují, že APL o vysoké aviditě se vyskytují u pacientů s trombózou a antifosfolipidovým syndromem (APS). Vyšetření avidity APL by mohlo být doplňujícím laboratorním ukazatelem, který by přinesl informaci využitelnou pro klasifikaci APS.

Klíčová slova:
protilátky proti ß2-glykoproteinu I – antikardiolipinové protilátky – antifosfolipidové protilátky – avidita – chaotropní látky – ELISA

Zdroje

1. Sangle NA, Smock KJ. Antiphospholipid antibody syndrome. Arch Pathol Lab Med, 2011;135:1092–1096.

2. Hughes GR. Hughes syndrome (the antiphospholipid syndrome): A disease of our time. Inflammopharmacology, 2011;19:69–73.

3. Miyakis S, Lockshin MD, Atsumi T, Branch DW, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (aps). J Thromb Haemost, 2006;4:295–306.

4. Ostrowski RA, Robinson JA. Antiphospholipid antibody syndrome and autoimmune diseases. Hematol Oncol Clin North Am, 2008;22:53–65, vi.

5. Sene D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev, 2008;7:272–277.

6. Tincani A, Taraborelli M, Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun Rev, 2010;9:200–202.

7. Shoenfeld Y, Twig G, Katz U, Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun, 2008;30:74–83.

8. Devreese K, Hoylaerts MF. Challenges in the diagnosis of the antiphospholipid syndrome. Clin Chem, 2010;56:930–940.

9. Malickova K, Sandova P, Janatkova I. Několik poznámek k laboratornímu vyšetřování antifosfolipidových protilátek. Epidemiol Mikrobiol Imunol, 2006;55:158–163.

10. Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev, 2010;9: A299–304.

11. Pengo V, Denas G, Banzato A, Bison E, et al. Interpretation of laboratory data and need for reference laboratories. Lupus, 2012;21:732–733.

12. Zager U, Irman S, Lunder M, Skarabot M, et al. Immunochemical properties and pathological relevance of anti-beta(2)-glycoprotein I antibodies of different avidity. Int Immunol, 2011;23:511–518.

13. Pohanka M. Monoclonal and polyclonal antibodies production – preparation of potent biorecognition element. J Appl Biomed, 2009;7:115–121.

14. Meroni PL, Shoenfeld Y. Predictive, protective, orphan autoantibodies: The example of anti-phospholipid antibodies. Autoimmun Rev, 2008;7:585–587.

15. Cucnik S, Bozic B, Kveder T, Tomsic M, et al. Avidity of anti-beta2-glycoprotein I and thrombosis or pregnancy loss in patients with antiphospholipid syndrome. Ann N Y Acad Sci, 2005;1051:141–147.

16. Cucnik S, Kveder T, Ulcova-Gallova Z, Swadzba J, et al. The avidity of anti-beta2-glycoprotein I antibodies in patients with or without antiphospholipid syndrome: A collaborative study in the frame of the European forum on antiphospholipid antibodies. Lupus, 2011;20:1166–1171.

17. Božič B, Čučnik S, Kveder T, Rozman B. Affinity and avidity of autoantibodies. In: Shoenfeld Y, Gershwin ME, Meroni P, editors. Autoantibodies. 2nd ed., Elsevier, 2007:21–28.

18. Gharavi A, Reiber H. Affinity and avidity of autoantibodies. In: Peter J, Shoenfeld Y, editors. Autoantibodies. 1st ed., Amsterdam: Elsevier, 1996:13–23.

19. Lappalainen M, Hedman K. Serodiagnosis of toxoplasmosis. The impact of measurement of IgG avidity. Ann Ist Super Sanita, 2004;40:81–88.

20. Steward MW. Antibody affinity: Immunogenetic aspects and relationship to immune complex disease. J Clin Pathol Suppl (R Coll Pathol), 1979;13:120–125.

21. Prince HE, Wilson M. Simplified assay for measuring Toxoplasma gondii immunoglobulin G avidity. Clin Diagn Lab Immunol, 2001;8:904–908.

22. Wilson KM, Di Camillo C, Doughty L, Dax EM. Humoral immune response to primary rubella virus infection. Clin Vaccine Immunol, 2006;13:380–386.

23. Shepherd SJ, Kean J, Hutchinson SJ, Cameron SO, et al. A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. J Clin Virol, 2013;57:29–35.

24. Štěpánová V, Plíšková L, Kubišová M, Štěpánová E, Bolehovská R, Boštíková V, Svobodová M. Využití testů avidity IgG protilátek v diagnostice cytomegalovirové infekce. Epidemiol Mikrobiol Imunol, 2011;60:115–120.

25. Strhársky J, Maďarová, L., Klement C. Laboratórna diagnostika toxoplazmózy. Epidemiol Mikrobiol Imunol, 2009;58:51–62.

26. Cui Z, Zhao MH. Avidity of anti-glomerular basement membrane autoantibodies was associated with disease severity. Clin Immuno, 2005;116:77–82.

27. Zachou K, Liaskos C, Rigopoulou E, Gabeta S, et al. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. Clin Immunol, 2006;119:203–212.

28. Suwannalai P, van de Stadt LA, Radner H, Steiner G, et al. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum, 2012;64:1323–1328.

29. Dimitrov JD, Lacroix-Desmazes S, Kaveri SV. Important parameters for evaluation of antibody avidity by immunosorbent assay. Anal Biochem, 2011;418:149–151.

30. Fialova L, Svarcova J, Bartos A, Malbohan I. Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum. Folia Microbiol (Praha) 2012;57:415–419.

31. Fialova L, Bartos A, Svarcova J, Malbohan I. Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis. PLoS One, 2011;6:e27476.

32. McCloskey N, Turner MW, Goldblatt TD. Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). J Immunol Methods, 1997;205:67–72.

33. Macdonald RA, Hosking CS, Jones CL. The measurement of relative antibody affinity by ELISA using thiocyanate elution. J Immunol Methods, 1988;106:191–194.

34. Inouye S, Hasegawa A, Matsuno S, Katow S. Changes in antibody avidity after virus infections: Detection by an immunosorbent assay in which a mild protein-denaturing agent is employed. J Clin Microbiol, 1984;20:525–529.

35. Woznicová V. Avidita imunoglobulinů G u infekčních onemocnění. Epidemiol Mikrobiol Imunol, 2004;53:4–11.

36. Dauner JG, Pan Y, Hildesheim A, Kemp TJ, et al. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes, 2012;26:73–80.

37. Almanzar G, Ottensmeier B, Liese J, Prelog M. Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate. J Immunol Methods, 2013;387:36–42.

38. Romero-Steiner S, Holder PF, Gomez de Leon P, Spear W, et al. Avidity determinations for Haemophilus influenzae Type b anti-polyribosylribitol phosphate antibodies. Clin Diagn Lab Immunol, 2005;12:1029–1035.

39. Liaskos C, Rigopoulou E, Zachou K, Georgiadou S, et al. Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. J Autoimmun, 2005;24:251–260.

40. Arias-Bouda LM, Kuijper S, Van der Werf A, Nguyen LN, et al. Changes in avidity and level of immunoglobulin G antibodies to Mycobacterium tuberculosis in sera of patients undergoing treatment for pulmonary tuberculosis. Clin Diagn Lab Immunol, 2003;10:702–709.

41. Cucnik S, Kveder T, Krizaj I, Rozman B, et al. High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis, 2004;63:1478–1482.

42. Metzger J, von Landenberg P, Kehrel M, Buhl A, et al. Biosensor analysis of beta2-glycoprotein I-reactive autoantibodies: Evidence for isotype-specific binding and differentiation of pathogenic from infection-induced antibodies. Clin Chem, 2007;53:1137–1143.

43. Sheng Y, Kandiah DA, Krilis SA. Anti-beta 2-glycoprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind to beta 2-glycoprotein I with low affinity: Dimerization of beta 2-glycoprotein I induces a significant increase in anti-beta 2-glycoprotein I antibody affinity. J Immunol, 1998;161: 2038–2043.

44. Tincani A, Spatola L, Prati E, Allegri F, et al. The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. J Immunol, 1996;157:5732–5738.

45. Cucnik S, Kveder T, Rozman B, Bozic B. Binding of high-avidity anti-beta2-glycoprotein I antibodies. Rheumatology (Oxford) 2004;43:1353–1356.

46. Agar C, van Os GM, Morgelin M, Sprenger RR, et al. Beta2-glycoprotein I can exist in 2 conformations: Implications for our understanding of the antiphospholipid syndrome. Blood, 2010;116:1336–1343.

47. Roggenbuck D, Egerer K, von Landenberg P, Hiemann R, et al. Antiphospholipid antibody profiling: Time for a new technical approach? Autoimmun Rev, 2012;11:821–826.

48. Vlachoyiannopoulos PG, Petrovas C, Tektonidou M, Krilis S, et al. Antibodies to beta 2-glycoprotein-I: Urea resistance, binding specificity, and association with thrombosis. J Clin Immunol, 1998;18:380–391.

49. Celli CM, Gharavi AE, Chaimovich H. Opposite beta2-glycoprotein I requirement for the binding of infectious and autoimmune antiphospholipid antibodies to cardiolipin liposomes is associated with antibody avidity. Biochim Biophys Acta, 1999;1416:225–238.

50. Dueymes M, Piette JC, Le Tonqueze M, Bendaoud B, et al. Role of beta 2-glycoprotein I in the anticardiolipin antibody affinity for phospholipid in autoimmune disease. Lupus, 1995;4:477–481.

51. Petrovas C, Vlachoyiannopoulos PG, Kordossis T, Moutsopoulos HM. Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: Comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. J Autoimmun, 1999;13:347–355.

52. Arvieux J, Renaudineau Y, Mane I, Perraut R, et al. Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost, 2002;87:599–605.

53. de Laat B, Derksen RH, de Groot PG. High-avidity anti-beta glycoprotein I antibodies highly correlate with thrombosis in contrast to low-avidity anti-beta glycoprotein I antibodies. J Thromb Haemost, 2006;4:1619–1621.

54. Cucnik S, Kveder T, Artenjak A, Ulcova Gallova Z, et al. Avidity of anti-beta2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Lupus, 2012;21:764–765.

55. Schlichtiger A, Baier C, Yin MX, Holmes AB, et al. Covalent attachment of functionalized cardiolipin on a biosensor gold surface allows repetitive measurements of anticardiolipin antibodies in serum. Anal Bioanal Chem, 2013;405:275–285.